H their viral C.I. 75535MedChemExpress Isoarnebin 4 reservoir. J Clin Invest 2005, 115:3250?255. Pace MJ, Graf EH
H their viral reservoir. J Clin Invest 2005, 115:3250?255. Pace MJ, Graf EH, Agosto LM, Mexas AM, Male F, Brady T, Bushman FD, O’Doherty U: Directly Infected Resting CD4+T Cells Can Produce HIV Gag without Spreading Infection in a Model of HIV Latency. PLoS Pathog 2012, 8:e1002818. Van Gulck E, Bracke L, Heyndrickx L, Coppens S, Atkinson D, Merlin C, Pasternak A, Florence E, Vanham G: Immune and viral correlates of “secondary viral control” after treatment interruption in chronically HIV-1 infected patients. PLoS One 2012, 7:e37792. Graf EH, Mexas AM, Yu JJ, Shaheen F, Liszewski MK, Di MM, Migueles SA, Connors M, O’Doherty U: Elite suppressors harbor low levels of integrated HIV DNA and high levels of PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/25432023 2-LTR circular HIV DNA compared to HIV+ patients on and off HAART. PLoS Pathog 2011, 7:e1001300. Blankson JN, Bailey JR, Thayil S, Yang HC, Lassen K, Lai J, Gandhi SK, Siliciano JD, Williams TM, Siliciano RF: Isolation and characterization of replicationcompetent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol 2007, 81:2508?518. Strain MC, Little SJ, Daar ES, Havlir DV, Gunthard HF, Lam RY, Daly OA, Nguyen J, Ignacio CC, Spina CA, et al: Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 2005, 191:1410?418. Deeks SG: HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 2011, 62:141?55. van Sighem A, Danner S, Ghani AC, Gras L, Anderson RM, de Wolf F: Mortality in patients with successful initial response to highly active antiretroviral therapy is still higher than in non-HIV-infected individuals. J Acquir Immune Defic Syndr 2005, 40:212?18. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sorensen HT, Vaeth M, Obel N: Survival of persons with and without HIV infection in Denmark, 1995?005. Ann Intern Med 2007, 146:87?5. The Antiretroviral Therapy Cohort Collaboration: Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008, 372:293?99. Soares RS, Tendeiro R, Foxall RB, Baptista AP, Cavaleiro R, Gomes P, Camacho R, Valadas E, Doroana M, Lucas M, et al: Cell-associated viral burden provides evidence of ongoing viral replication in aviremic HIV-2 -infected patients. J Virol 2011, 85:2429?438. Hunt PW, Hatano H, Sinclair E, Lee TH, Busch MP, Martin JN, McCune JM, Deeks SG: HIV-specific CD4+ T cells may contribute to viral persistence in HIV controllers. Clin Infect Dis 2011, 52:681?87. Hatano H, Jain V, Hunt PW, Lee TH, Sinclair E, Do TD, Hoh R, Martin JN, McCune JM, Hecht F, et al: Cell-Based Measures of Viral Persistence Are Associated With Immune Activation and Programmed Cell Death Protein 1 (PD-1)-Expressing CD4+ T cells. J Infect Dis 2012 [Epub ahead of print]. Shen L, Siliciano RF: Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J Allergy Clin Immunol 2008, 122:22?8. Maldarelli F: Targeting viral reservoirs: ability of antiretroviral therapy to stop viral replication. Curr Opin HIV AIDS 2011, 6:49?6. Joos B, Fischer M, Kuster H, Pillai SK, Wong PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/26104484 JK, Boni J, Hirschel B, Weber R, Trkola A, Gunthard HF: HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci U S A 2008, 105:16725?6730. Ramratnam B, Mittler JE, Zhang L, Boden D, Hurley A, Fang F, Macken CA, Perelson AS, Markowitz M, Ho DD:.